Company Overview of DynPort Vaccine Company LLC
DynPort Vaccine Company LLC provides biopharmaceutical product development programs for government agencies in the United States and internationally. It offers government contracting for business and biopharmaceutical product development, which include program management, risk identification and management, subcontracts management, and financial reporting; health and security protection services for the U.S. and allied governments in protecting soldiers and civilians against emerging diseases and possible bioterror threats; and infectious disease therapeutics. The company also provides consulting services to biotechnology and pharmaceutical companies. It serves government agencies, biotech c...
64 Thomas Johnson Drive
Frederick, MD 21702
Founded in 1997
Key Executives for DynPort Vaccine Company LLC
Associate Director of Communications
Director of Program Management Office
Compensation as of Fiscal Year 2017.
DynPort Vaccine Company LLC Key Developments
FDA Grants Orphan Drug Designation to DynPort Vaccine Company for Plague Vaccine
Mar 8 17
DynPort Vaccine Company LLC was granted Orphan Drug Designation from the U.S. Food and Drug Administration. DVC is developing the recombinant rF1V plague vaccine on behalf of the U.S. Department of Defense (DoD). The vaccine will be used for pre-exposure prophylaxis to combat infection with Yersinia pestis, the causative agent of plague. DVC is a contractor for the Medical Countermeasure Systems Joint Vaccine Acquisition Program (MCS-JVAP) and the sponsor of the associated Investigational New Drug Application for the plague vaccine.
DynPort Vaccine Company LLC Wins Contract
Dec 27 16
CSRA Inc.'s wholly-owned subsidiary, DynPort Vaccine Company LLC received a multiple-award, indefinite-delivery, indefinite-quantity (IDIQ) contract to manage a variety of medical product development initiatives for the National Institute of Allergy and Infectious Diseases (NIAID). CSRA'sDynPort Vaccine Company is one of four awardees to receive the IDIQ valued up to $159 million, with a period of performance of up to 10 years. Under the contract, the company will develop manufacturing processes and analytical test methods, perform product characterization, conduct manufacturing following current good manufacturing practices (cGMP) and provide regulatory services to support the development of new therapies to treat infectious diseases.
DynPort Vaccine Co. Wins $159.44 Million Federal Contract
Sep 8 16
DynPort Vaccine Co. LLC, Frederick, Maryland, won a federal contract valued at up to $159,444,814 from the U.S. Department of Health and Human Services National Institutes of Health for preclinical services for biopharmaceutical product development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries